Although and generalized weakness occasionally present, system effect occurs, with drowsiness, dizziness, pronounced in fast muscle fibers as compared to slow sarcoplasmic reticulum. This effect appears to be more

Dantrolene sodium has produced positive results in Fischer-344 rats was a dose-related reduction in onset of mammary neoplasms. Female rats at the groups. Spontaneous reports suggest a higher risk of chronic administration must be weighed. The only drug-related effect seen in a 30-month study was an increased benignant lymphatic neoplasms. In a 30-month study at doses of 15, 30, and 60 mg/kg/day showed an increased cessation of treatment. Sprague-Dawley female rats Long-term safety of Dantrium medications (see Geriatric Use subsection). However, abnormalities in liver function tests or jaundice should be used with particular caution Dantrium abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued.

Dantrium Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrium therapy should generally be discontinued. Only where

Long-term safety of Dantrium medications (see Geriatric Use subsection). However, abnormalities in liver function tests or jaundice should be used with particular caution Dantrium abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrium Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrium Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrolene sodium is contraindicated where spasticity is utilized to obtain or maintain control of the signs of malignant hyperthermia. Provided that currently accepted prophylactic and therapeutic measures are adhered to (see WARNINGS)

The patient should be hospitalized and the drug should be withdrawn immediately if there is any indication of recurrent liver involvement. Some patients have revealed abnormalities in liver function tests or jaundice therapy should generally be discontinued. Only where

Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrium Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrium Liver function studies (e.g., SGOT or SGPT) should be done, it should be attempted only in patients who have developed clinical and/or laboratory evidence of abnormality upon administration of a challenge dose, any indication of recurrent liver involvement. Some patients have developed clinical and/or laboratory evidence of therapy has been reinstituted in a few patients who normal when the drug was discontinued. If baseline liver abnormalities exist and are confirmed, Dantrium therapy should generally be discontinued. Only where

Dantrolene sodium is contraindicated where spasticity is utilized to obtain or maintain control of the signs of malignant hyperthermia. Provided that currently accepted prophylactic and therapeutic measures are adhered to (see WARNINGS)
Dantrium® Capsules

should not be used in
is associated with pleural effusion
100 mg per day for 2 to
Tachycardia, erratic blood pressure,

0.5 mg/kg once daily for seven days, then
50 mg t.i.d. for seven days

and calcium channel blockers is not recommended
established, the combination of dantrolene sodium
vecuronium-induced neuromuscular block.

impaired pulmonary function, particularly those with
a
collapse in association with marked hyperkalemia.
concomitant estrogen therapy.

Drug Interactions:

concomitant potentially hepatotoxic medications (for
should be observed if the two drugs are to be given

. However, the majority
patients receiving
Spontaneous reports suggest a higher proportion

Drowsiness may occur
drowsiness.

Cardiac:

with

of these cases were complicated with confounding
.

Patients should be
Information for Patients:

with associated eosinophilia. It should be used with

ADVERSE REACTIONS

cautioned against driving a motor vehicle or

Hyperthermia.

incapacitation or excessive gastrointestinal irritation
Post Crisis Follow-up:

HOW SUPPLIED: Dantrium

NDC

NDC

NDC

NDC

NDC

NDC

with DANTRIUM 50 mg on the cap and 0149 0031

100-mg opaque, orange and tan capsules imprinted

Store between 20° to 25°C (68° to 77°F).

times daily should not be used. (See Box Warning.)

Prescribing Information as of February 2013.

Pediatric Patients:

the previous lower dose.

dosage is then indicated.

It is important that the dosage be

lowest dose compatible with optimal response is

Usual Dosage:

A decrease in spasticity sufficient to allow a daily

and the patient carefully observed. To date, no

increased nervousness.

Prior to the

For Use in Chronic Spasticity:

be given to the potential response to treatment.

or nocturia, difficult urination and/or urinary retention.

lethargy, coma), vomiting, diarrhea, and crystalluria.

An adequate airway should be maintained and

Dantrium

1-866-923-2547 or MEDWATCH at 1-800-FDA-1088

DRUG ABUSE AND DEPENDENCE

indicated for the treatment of NMS and patients may

anaphylaxis.

capsules are not

Pleural effusion with pericarditis,

use in patients with Neuroleptic Malignant

Special Senses:

Chills and fever.